ACE-083

Pharmacokinetics

ACE-083 is a synthetically engineered ligand trap, and works primarily by blocking signals that inhibit muscular growth.[2] Within the body, there are proteins that restrict muscle gain, called myostatins. In the absence of ACE-083, myostatins block chemical signals that lead to muscle growth. When administered, ACE-083 binds to the myostatins. This binding results in uninhibited muscle growth.[3]

Scientific Studies

There have been multiple human and animal studies of ACE-083, pointing towards a correlation between its administration and local muscle growth. In one animal study, subjects were injected with ACE-083 twice per week, over four weeks. Findings indicated muscle growth localized to the site of injection.[2] Another study conducted on postmenopausal women provided similar findings. All 42 non-placebo subjects appeared to demonstrate higher muscle volume where ACE-083 was injected.[4] Both of these studies show that this peptide may promote higher rates of muscle growth.

Sources:

[1] https://strongly.mda.org/fda-grants-orphan-drug-designation-to-acceleron-pharmas-ace-083-muscle-growth-drug-for-charcot-marie-tooth-disease/

[2] https://www.nmd-journal.com/article/S0960-8966(15)00304-1/abstract

[3] https://acceleronpharma.com/wp-content/uploads/2017/03/20141009-ACE-083-20141009-ACE-083-a-ligand-trap-for-members-of-the-TGFB-superfamily-increases-muscle-mass-loc.pdf

[4] https://www.ncbi.nlm.nih.gov/pubmed/29486514

[5] https://charcot-marie-toothnews.com/2018/07/26/preliminary-cmt-phase-2-trial-results-ace-083-presented/